A federal judge has rejected standing challenges brought by numerous pharmaceutical companies in an attempt to dismiss several antitrust and consumer protection class action claims leveled by entities that either purchased or resold generic drugs at allegedly inflated prices.

The defendants, which consist of 25 pharmaceutical companies, had argued that plaintiffs did not have standing to bring claims based on state laws in jurisdictions where the class representatives did not either purchase or resell the drugs at issue. Specifically, the defendants contended the plaintiffs did not have Article III standing to bring the claims.